Compare HHH & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HHH | IMVT |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.3B |
| IPO Year | N/A | N/A |
| Metric | HHH | IMVT |
|---|---|---|
| Price | $82.67 | $26.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $90.00 | $29.13 |
| AVG Volume (30 Days) | 396.4K | ★ 1.6M |
| Earning Date | 02-19-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 234.52 | N/A |
| EPS | ★ 5.10 | N/A |
| Revenue | ★ $1,834,033,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.38 | N/A |
| P/E Ratio | $16.07 | ★ N/A |
| Revenue Growth | ★ 69.81 | N/A |
| 52 Week Low | $61.41 | $12.72 |
| 52 Week High | $91.07 | $27.80 |
| Indicator | HHH | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 52.97 | 53.63 |
| Support Level | $80.95 | $25.43 |
| Resistance Level | $83.65 | $27.37 |
| Average True Range (ATR) | 1.63 | 1.19 |
| MACD | 0.37 | -0.11 |
| Stochastic Oscillator | 84.10 | 47.74 |
Howard Hughes Holdings Inc owns, manages, and develops commercial, residential, and mixed-use real estate throughout the USA. Its portfolio is strategically positioned to meet and accelerate development based on market demand, resulting in one of the strongest real estate platforms in the country. It operates through four business segments: Operating Assets, MPCs, Strategic Developments and Seaport.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.